Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall ...

By Amina Niasse NEW YORK, Jan 28 (Reuters) - Telehealth company Ro has had an influx of new customers seeking the newly ...

The pill version of Wegovy seems to work just as well as the injectable form, but there are some key differences between the ...

Novo Nordisk (NVO) may see a post-earnings dip as Q4 includes conservative 2026 guidance despite oral Wegovy momentum. Click ...

According to Lilly, a New Drug Application for orforglipron for the treatment of adults with obesity or overweight has been submitted to the Food and Drug Administration.

A NEW jab set to rival the likes of Mounjaro and Wegovy helped people lose up to 22 per cent of their body weight in less ...

By Sriparna Roy Jan 23 (Reuters) - Novo Nordisk's Wegovy pill was prescribed more than 18,000 times in the U.S. in the first ...

FDA has approved Novo Nordisk's once daily oral Wegovy pill for obesity and cardiovascular risk reduction, and the product has now launched in the U.S. The oral format offers an alternative to ...

With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the ...

Novo Nordisk (NVO) stock is in focus as the company's advertising expenditure for its GLP-1s, Wegovy and Ozempic, exceeds that for Lilly's (LLY) rivals. Read more here.

About 20 years ago, the U.S. Food and Drug Administration approved the first GLP-1 medication for Type 2 diabetes. Today, the landscape has shifted, as the agency has approved various ...

The phase 2 trial of CT-388, a once-weekly subcutaneous injection acquired as part of its $2.7 billion takeover of Carmot ...